DUBLIN--(BUSINESS WIRE)--The "Chronic Disease Management: Therapeutics, Device Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
The Chronic Disease Management Market was valued at USD 726.3 billion in 2024, and is expected to reach USD 1.1 trillion by 2029, rising at a CAGR of 8.10%.
Growth of the global market is attributed to factors such as the increasing prevalence of chronic conditions, along with the adoption of personalized medicine and remote monitoring solutions. In this report, the market is segmented by product type, application, end user, and geography. Product types include pharmaceutical drugs and biologics, medical devices, and digital therapeutics.
Pharmaceutical drugs and biologics are further segmented into drugs and biologics. Medical devices are further segmented into traditional devices and wearable devices. Applications include the following diseases: cancer, metabolic disorders, cardiovascular diseases, immunological disorders, respiratory diseases, musculoskeletal disorders, gastrointestinal disorders, neurological diseases and psychiatric disorders. The end-user market is segmented into home care, hospitals and others. The report also provides a regional market analysis of drug-device combinations.
Report Scope
Chronic disease management encompasses drugs and medical device-based techniques. This report can serve as an analytical business tool to evaluate the global market for therapeutics and advanced device technologies for chronic disease management. This report analyzes market trends with data from 2023, estimates for 2024 and projections of CAGRs through 2029.
It evaluates the market potential for chronic disease management and provides an analysis of the competitive landscape. The report covers the market's drivers, restraints and opportunities, as well as the market shares of leading companies. The market is segmented into product type, application, end user, and geographic region. Product segments include pharmaceuticals and biologics (drugs and biologics), medical devices (traditional and wearable devices) and digital therapeutics. Application areas (disease categories) are cancer, metabolic disorders, musculoskeletal disorders, cardiovascular conditions, immunological disorders, gastrointestinal disorders, respiratory diseases, neurological conditions, psychiatric conditions, and others. End users are categorized into hospitals and other facilities and home care.
The global market is segmented into the regions of North America, Europe, Asia-Pacific, and the Rest of the World (RoW). This analysis also includes broken down by country.
The report includes:
- 106 data tables and 39 additional tables
- Analyses of global market trends, with historic market revenue data (sales figures) from 2021 to 2022, estimates for 2023, forecast for 2024, and projected CAGRs through 2029
- Estimates of the current market size and revenue prospects of the global market, along with a market share analysis by product type, application, end user, and region
- Analysis of the market dynamics, technological advances, regulations, and the macroeconomic factors influencing the market
- A look into the current state of chronic diseases and disorders, with an emphasis on advance needle-free drug delivery technologies, diagnostic methods, and smart device technologies that support chronic disease management
- Identification of promising new drugs, biologics, and emerging device technologies still in the development and testing stages
- A look at the regulatory structure for pharmaceuticals and medical devices, pricing and reimbursement structure, marketed and pipeline products and their potential for commercialization
- A look at the recent patent grants
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, ESG score analysis, and the ESG practices of leading companies
- Analysis of the industry structure, including company market shares, strategic alliances, M&A activity and a venture funding outlook
- Profiles of market leaders in the Chronic Disease Management market, including Abbott, Bristol Myers Squibb Co., F. Hoffmann-La Roche Ltd., Pfizer and Johnson & Johnson Services.
Key Attributes:
Report Attribute | Details |
No. of Pages | 157 |
Forecast Period | 2024 - 2029 |
Estimated Market Value (USD) in 2024 | $726.3 Billion |
Forecasted Market Value (USD) by 2029 | $1100 Billion |
Compound Annual Growth Rate | 8.1% |
Regions Covered | Global |
Key Topics Covered:
Chapter 1 Executive Summary
Chapter 2 Market Overview
- Market Insights
- Regulatory Background
- Chronic Disease Management Act of 2021 (CDMA)
- Regional Regulatory Frameworks for Chronic Disease Medical Devices
- Regulatory Systems for Pharmaceuticals, by Region
- Pricing and Reimbursement for Medical Devices, by Region
- Pricing and Reimbursement for Pharmaceuticals, by Region
Chapter 3 Market Dynamics
-
Market Drivers
- Growing Aging Population Worldwide
- Growing Prevalence of Chronic Diseases
- Technological Advances
- Government Initiatives and Funding
-
Market Restraints
- High Cost of Treatments
- Patent Expiry and Shorter Product Life Cycles
- Regulatory Issues for Drugs, Medical Devices and Software Applications
- Limited Access in Low-Income Regions
-
Market Challenges
- Medication Nonadherence
- Regulatory Challenges
- Challenges with Digital Health Applications
-
Market Opportunities
- Digital Therapeutics
- Strong Research and Development Initiatives from Key Market Players
Chapter 4 Market Segmentation Analysis
-
Market Analysis, by Product Type
- Pharmaceutical Drugs and Biologics
- Medical Devices
- Digital Therapeutics
-
Market Analysis, by Application
- Oncological Diseases
- Metabolic Disorders
- Cardiovascular Diseases
- Immunological Disorders
- Respiratory Diseases
- Musculoskeletal Disorders
- Chronic Gastrointestinal Diseases
- Neurological Diseases
- Psychiatric Disorders
- Other Applications
-
Market Analysis, by End User
- Home Care
- Hospitals and Others
- Geographic Breakdown
- Market Analysis, by Region
Chapter 5 Emerging Trends and Technologies
- Mobile Health Technology
- AI, Machine Learning, and Deep Learning in Chronic Care Management
- Remote Patient Monitoring Devices
- Digital Therapeutics
- Biowearable Technology
- Glucose-Sensing Contact Lenses
- Recent Approvals and Launches of Novel Drug and Device Products
Chapter 6 ESG Developments
- ESG in the Chronic Disease Management Industry
- ESG Risk Ratings
- BCC Research Viewpoint
Chapter 7 Competitive Landscape
- Mergers, Acquisitions and Collaborations
- Patent Analysis
- Patent Review, by Assignee Country
- Patent Review, by Year
- Company Share Analysis
- Strategic Alliances
Company Profiles
- Abbott
- Amgen
- AstraZeneca
- Boston Scientific
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- GSK
- Johnson & Johnson Services
- Medtronic
- Pfizer
For more information about this report visit https://www.researchandmarkets.com/r/qyaqty
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.